Hemogenyx Pharmaceuticals Plc · LSE:HEMO
Hemogenyx Pharmaceuticals — Investor Presentation (July 2021)
16 slides from Hemogenyx Pharmaceuticals's investor presentation, Jul 2, 2021
Slide 1: A New Era for the treatment of blood diseases
A NEW ERA for the treatment of blood diseases Corporate Presentation July 2021
Slide 2: Important Notice
IMPORTANT NOTICE The information contained in this Presentation has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (“FSMA”). Reliance upon this Presentation for the purpose of engaging in any investment activity may expose an individual to
Slide 3: Hemogenyx Pharmaceuticals Management Team
Hemogenyx Pharmaceuticals Management Team Dr Vladislav Sandler PhD Professor Sir Marc Feldmann Andrew Wright FOUNDER AND CHIEF EXECUTIVE OFFICER CHAIRMAN CO. SEC./FINANCIAL CONTROLLER Non-Executive Directors Alexis Sandler ■ Co-founder and COO in US ■ Attorney specialising in intellectual property ■
Slide 4: Hemogenyx Pharmaceuticals Advisory Board
Hemogenyx Pharmaceuticals Advisory Board Hemogenyx benefits from an experienced commercial and scientific advisory board which includes two Lasker awardees (aka ‘the American Nobels’) Professor Sir Marc Feldmann Dr H. Michael Shepard Dr Koen van Besien CHAIRMAN SCIENTIFIC ADVISOR SCIENTIFIC ADVISOR
Slide 5: Principal Product Candidates
Hemogenyx Pharmaceuticals Principal Product Candidates Advanced CDX CAR-T CBR platform Undisclosed Hematopoietic Chimera (ApbHC) ▪ Targeting relapsed/ ▪ Targeting relapsed/ ▪ Programmed immune ▪ Discovery and validation ▪ Platform technology for refractory acute myeloid refractory acute myeloid cell
Slide 6: The Problem: AML & Conditioning
The Problem AML & Conditioning A Bone Marrow or Hematopoietic Stem Cell Transplant (HSCT) is a potentially life-saving option in treating blood diseases such as Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) 1 R/R AML Is Almost Universally Fatal ▪ The only curative treatment is an allogenei
Slide 7: The Solution: CDX Bi-specific Antibody
The Solution CDX Bi-specific Antibody A novel bispecific monoclonal antibody (CDX; FLT3-CD3) to eliminate malignancy in patients with FLT3+ R/R AML and condition them for bone marrow transplantation 1 FLT3 Expression ▪ FLT3 is expressed in CD34+ HSC, early HP and Dendritic Cells ▪ FLT3 is expressed
Slide 8: CDX Antibody Mechanism of Action
CDX Antibody Mechanism of Action CDX redirects T cells to attack unwanted FLT3 + cells such as R/R AML, HSC and hematopoietic progenitors ▪ 8
Slide 9: CDX Antibody Benefits of CDX
CDX Antibody Benefits of CDX ▪ Use of FLT3-CD3 bispecific antibodies to eliminate HSC/HP will make conditioning safer by eliminating the side effects that accompany traditional CDX Antibody methods of patient preparation for BM/HSC transplantation. Developed in collaboration with a global biopharmac
Slide 10: CDX Antibody Summary
CDX Antibody Summary ▪ High affinity – anti-FLT3 humanized monoclonal antibody binds FLT3 with high affinity (40 pM) and low Kd (10-12) ▪ No FLT3L competition – targets the most distant extracellular domain of FLT3 eliminating competition with FLT3L (a unique epitope) ▪ Partial efficacy and safety c
Slide 11: CDX Antibody Pre-clinical and Clinical Path
CDX Antibody Pre-clinical and Clinical Path 1 Pre-clinical I. Pre-clinical ADME/toxicology studies of FLT3-CD3 antibodies will be conducted in Rhesus monkeys (FLT3-CD3 antibodies are Rhesus monkey cross-reactive) to demonstrate: ▪ Safety ▪ Partial efficacy Conducting pre-clinical toxicology studies
Slide 12: CAR T Cells Autologous CAR-T Therapy
CAR T Cells Autologous CAR-T Therapy T cell activation and CAR-T cell Infusion of Apheresis T cell isolation programming with anti-FLT3 Expansion CAR-T cells CAR into patients T cells Patient’s white Transduction for CAR Infusion of CAR-Ts blood cells expression to the same patient collection Anti-C
Slide 13: ApbHC – Humanized Mouse Model
Immugenyx ApbHC – Humanized Mouse Model Immugenyx has developed a novel type of humanized mice that possess a functional human immune system What are ApbHC? Validated by multiple collaborations Possible applications ▪ Mice with high levels of human hematopoietic ▪ Assessment of immunogenicity of bio
Slide 14: Hemogenyx Pharmaceuticals Summary
Hemogenyx Pharmaceuticals Summary ▪ End-to-end solution: Novel treatments aim to remove need for dangerous conditioning and potentially eliminate need for bone marrow donors ▪ De-risked: Established sound proof-of-principle in humanized animal studies ▪ Fast tracking: Lead product expected to be rea
Slide 15: Hemogenyx Pipeline
Hemogenyx Pipeline Target Lead Lead Candidate IND-enabling Agreements/ Asset Phase I/IIa Phase II identification identification optimisation selection studies Collaborations CDX bi- specific Current state Cash on hand ‘GlobalCo’ antibody CAR T cell Current state Cash on hand Center for Cellular Immu
Slide 16: Get in Touch
Hemogenyx Pharmaceuticals plc Registered in England and Wales as company number 08401609 at 5 Fleet Place, London EC4M 7RD, UK GET IN T O U C H +1 (347) 735-8380 hemogenyx@hemogenyx.com
Hemogenyx Pharmaceuticals — Investor Presentation (July 2021) on 6ix